Minimal Change Glomerulonephritis clinical trials
13 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- taVNS for FRNS in Children
- A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
- Atacicept in Multiple Glomerular Diseases
- Study of WAL0921 in Patients With Glomerular Kidney Diseases
- PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
- Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
- Nephrotic Syndrome Study Network
- Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
- NEPTUNE Match Study
- SLIT ABS: Study on Patients With Autoimmune Podocytopathy
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Minimal Change Glomerulonephritis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.